Form 8-K - Current report:
SEC Accession No. 0001104659-26-000748
Filing Date
2026-01-05
Accepted
2026-01-05 17:30:29
Documents
15
Period of Report
2026-01-01
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2534601d1_8k.htm   iXBRL 8-K 33586
2 EXHIBIT 10.1 tm2534601d1_ex10-1.htm EX-10.1 72532
3 EXHIBIT 99.1 tm2534601d1_ex99-1.htm EX-99.1 13771
7 GRAPHIC tm2534601d1_ex99-1img001.jpg GRAPHIC 1954
  Complete submission text file 0001104659-26-000748.txt   311731

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA hypd-20260101.xsd EX-101.SCH 3026
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE hypd-20260101_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hypd-20260101_pre.xml EX-101.PRE 22366
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2534601d1_8k_htm.xml XML 3218
Mailing Address 295 MADISON AVENUE SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE SUITE 2400 NEW YORK NY 10017 833-393-6684
HYPERION DEFI, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 26507977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)